Gilead Sciences

$62.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.06 (+1.73%) Today
+$0.04 (+0.06%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell GILD and other stocks, options, and ETFs commission-free!

About GILD

Gilead Sciences, Inc. Common Stock, also called Gilead Sciences, is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA. The listed name for GILD is Gilead Sciences, Inc. Common Stock.

CEO
Daniel P. O'Day
Employees
11,800
Headquarters
Foster City, California
Founded
1987
Market Cap
79.44B
Price-Earnings Ratio
630.39
Dividend Yield
4.43
Average Volume
7.96M
High Today
$62.63
Low Today
$61.65
Open Price
$61.75
Volume
7.33M
52 Week High
$85.97
52 Week Low
$56.56

GILD News

MarketWatch10h

Gilead Sciences Inc. stock rises Monday, still underperforms market

Shares of Gilead Sciences Inc. GILD, +1.73% rose 1.73% to $62.46 Monday, on what proved to be an all-around positive trading session for the stock market, with
BenzingaFeb 27

The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings

Benzinga Most Food and Drug Administration decisions scheduled for February were positive, and more importantly five new molecular entities passed FDA muster.
ReutersFeb 23

UPDATE 1-EU drug watchdog to weigh in on extended use for remdesivir by summer

(Writes through with details from statement, background) Feb 23 (Reuters) - Europe’s drugs regulator said on Tuesday it was expecting to give an opinion before

GILD Earnings

$0.00
$0.73
$1.46
$2.19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected Apr 29, After Hours

You May Also Like

VEEV
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure